Sitrin Capital Management’s Corcept Therapeutics CORT Stock Holding History

Sitrin Capital Management’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-15,000	Closed	-$182K	–	37
2019 Q4	$182K	Hold	15,000	–	–	0.09%	37
2019 Q3	$212K	Hold	15,000	–	–	0.12%	37
2019 Q2	$167K	Hold	15,000	–	–	0.09%	38
2019 Q1	$176K	Hold	15,000	–	–	0.09%	36
2018 Q4	$200K	Hold	15,000	–	–	0.12%	35
2018 Q3	$210K	Hold	15,000	–	–	0.11%	35
2018 Q2	$236K	Hold	15,000	–	–	0.13%	37
2018 Q1	$247K	Hold	15,000	–	–	0.16%	36
2017 Q4	$271K	Hold	15,000	–	–	0.17%	36
2017 Q3	$290K	Hold	15,000	–	–	0.19%	36
2017 Q2	$177K	Buy	+15,000	New	+$163K	0.12%	37
2017 Q1	–	Sell	-10,000	Closed	-$73K	–	37
2016 Q4	$73K	Sell	10,000 -30,000	-75%	-$235K	0.06%	36
2016 Q3	$260K	Hold	40,000	–	–	0.2%	34
2016 Q2	$218K	Hold	40,000	–	–	0.18%	35
2016 Q1	$187K	Hold	40,000	–	–	0.15%	37
2015 Q4	$154K	Buy	+40,000	New	+$180K	0.13%	37

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

Sitrin Capital Management's CORT Position: Q1 2020 in Review

Sitrin Capital Management sold out of Corcept Therapeutics (CORT) in Q1 2020, closing a stake of 15,000 shares — an estimated $182K sold.

Sitrin Capital Management first reported a position in CORT in Q4 2015 and held it in 16 quarters. The position peaked at $290K in Q3 2017. 204 funds tracked by Wall St. Rank hold CORT as of Q1 2020.

Sitrin Capital Management reported no remaining Corcept Therapeutics position as of Q1 2020 after selling out during the quarter.
Sitrin Capital Management sold 15,000 Corcept Therapeutics shares in Q1 2020, an estimated $182K.
Sitrin Capital Management first reported a position in Corcept Therapeutics in Q4 2015 and held it in 16 quarters.
Sitrin Capital Management's Corcept Therapeutics position peaked at $290K in Q3 2017.
204 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2020.

Based on Sitrin Capital Management's 13F filing for Q1 2020, filed 11 May 2020.